ClinicalTrials.gg
CompletedNCT02660229SWITCHUpdated Nov 19, 2018Results posted

An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.

A Phase 4 interventional study of Oxycodone Hydrochloride and Morphine Sulphate in Cancer Pain, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing oxycodone in Cancer Pain — 1 open to participants now, 1 under way, none of them phase 3. Oxycodone · Cancer Pain.

Enrollment
8th of 10
66 · median 153
Started
2015
the only one that year
Phase 4
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
3 of 10
Mundipharma Korea Ltd

Among the 10 studies testing oxycodone in Cancer Pain, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 7 in phase 4, and was the 7th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

1 of the 10 studies testing oxycodone in Cancer Pain is open now. Recruiting first, the newest first:

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Cancer Pain studies recruiting now, 32 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing oxycodone in Cancer Pain, or all of them as a file.
02

Study summary

The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.

Read the detailed description

5days, Multi-centers, Randomization, Open label, Parallel, Active Comparator, Phase 4 Study.

03

Conditions studied

  • Cancer Pain

Browse trials for

Keywords

  • Intravenous injection in cancer pain
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult men and women aged 19 years or more
  2. Patients with cancerous pain who are hospitalized or scheduled for hospitalization at Screening and not planned to be discharged during the study
  3. Patients with mean moderate to severe pain over the past 7 days at Screening as verbally confirmed (NRS 4 or higher)
  4. Subjects who voluntarily signed the Form for the study
  5. Subjects who are capable of understanding details of the study and verbal communication on pain intensity

Exclusion criteria

Exclusion Criteria:

  1. Patients who reached the narcotic analgesic dose corresponding to the followings for cancerous pain treatment immediately prior to Screening (oral morphine dose 195mg/day, oral oxycodone dose 130mg/day, patch fentanyl dose 75μg/hour)
  2. Patients with a medical history of to an ingredient of oxycodone hydrochloride or morphine sulfate or other narcotic analgesics
  3. Patients who have and cautions when study drugs administered.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Oxycodone Hydrochloride

    Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride

    Drug: Oxycodone Hydrochloride

  • Active comparator
    Morphine Sulphate

    Brand name: BC Morphine sulfate Generic name: Morphine sulfate

    Drug: Morphine Sulphate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.

    For the pain assessment value for efficacy assessment, Subjects perform pain grading through Numeric rating score(NRS) from 1 to 10 for the mean pain intensity over the past 7 days at Screening, and mean pain intensity over the past 24 hours at Baseline (Day 0), Day 1, Day 2, Day 3, Day 4, Day 5. Verbal measurement can be conducted by subjects without using visual data. '0' indicates 'no pain', and as the number increases, the pain gets more severe, and '10' indicates the worst pain.

    Time frame: 5 days

Secondary outcomes

  1. Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration

    The dose of the study drugs intravenously administered was checked and recorded every day. The information on the dose administered from baseline to each assessment time point was collected based on records on the chart, and in the event of dose change/end of treatment, pertinent date and time, and dose were recorded accurately on the chart. ‡ Total administered dose of the study drugs (mg)= IV infusion (mg/hr) \* \[(End date - start date) \* 24 + (end time - start time)\] + bolus injection (mg)

    Time frame: 5 days

  2. Patient's Overall Satisfaction With Each Continuous Infusion on Day 5 After Randomization

    The subjects made an assessment of overall treatment satisfaction regarding pain using the PGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse) after baseline and at the end of the study (Day 5).

    Time frame: 5 days

  3. Investigator's Overall Satisfaction With IV Infusion on 5 Days After Randomization

    The investigators made an assessment using the CGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse).

    Time frame: 5 days

07

Results

Posted Nov 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneOxycodone HydrochlorideMorphine Sulphate
Started3432
Safety analysis set3432
Fas set3332
Per protocol set2829
Completed3231
Not completed21
Withdrew: Adverse event20
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.

For the pain assessment value for efficacy assessment, Subjects perform pain grading through Numeric rating score(NRS) from 1 to 10 for the mean pain intensity over the past 7 days at Screening, and mean pain intensity over the past 24 hours at Baseline (Day 0), Day 1, Day 2, Day 3, Day 4, Day 5. Verbal measurement can be conducted by subjects without using visual data. '0' indicates 'no pain', and as the number increases, the pain gets more severe, and '10' indicates the worst pain.

Time frame:
5 days
Reported as:
Mean · units on a scale
Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.
units on a scaleOxycodone HydrochlorideMorphine Sulphate
Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.-3.52 ± 2.17-3.13 ± 1.84
SecondaryTotal Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration

The dose of the study drugs intravenously administered was checked and recorded every day. The information on the dose administered from baseline to each assessment time point was collected based on records on the chart, and in the event of dose change/end of treatment, pertinent date and time, and dose were recorded accurately on the chart. ‡ Total administered dose of the study drugs (mg)= IV infusion (mg/hr) \* \[(End date - start date) \* 24 + (end time - start time)\] + bolus injection (mg)

Time frame:
5 days
Reported as:
Mean · mg
Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration
mgOxycodone HydrochlorideMorphine Sulphate
Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration226.80 ± 110.44226.64 ± 135.13
SecondaryPatient's Overall Satisfaction With Each Continuous Infusion on Day 5 After Randomization

The subjects made an assessment of overall treatment satisfaction regarding pain using the PGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse) after baseline and at the end of the study (Day 5).

Time frame:
5 days
Reported as:
Count of participants · Participants
Patient's Overall Satisfaction With Each Continuous Infusion on Day 5 After Randomization
ParticipantsOxycodone HydrochlorideMorphine Sulphate
1:Very much improved98
2: Much Improved1010
3: Minimally improved1212
4: No change11
5: Minimally worse00
6: Much worse00
7: Very much worse00
SecondaryInvestigator's Overall Satisfaction With IV Infusion on 5 Days After Randomization

The investigators made an assessment using the CGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse).

Time frame:
5 days
Reported as:
Count of participants · Participants
Investigator's Overall Satisfaction With IV Infusion on 5 Days After Randomization
ParticipantsOxycodone HydrochlorideMorphine Sulphate
1: Very much improved109
2: Much improved1615
3: Minimal improved56
4. No change11
5. Minimally worse00
6. Much worse00
7. Very much worse00

Adverse events

Collected over 5 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxycodone Hydrochloride0/34 (0%)3/34 (8.8%)14/34 (41.2%)
Morphine Sulphate0/32 (0%)2/32 (6.3%)11/32 (34.4%)
Most frequent serious events
Most frequent serious events
EventOxycodone HydrochlorideMorphine Sulphate
DyspnoeaRespiratory, thoracic and mediastinal disorders0/341/32
NeutropeniaBlood and lymphatic system disorders1/341/32
PyrexiaGeneral disorders1/340/32
Platelet count decreasedInvestigations1/340/32
Most frequent other events
Showing 10 of 12
Most frequent other events
EventOxycodone HydrochlorideMorphine Sulphate
ConstipationGastrointestinal disorders7/343/32
NauseaGastrointestinal disorders4/345/32
DizzinessNervous system disorders2/343/32
SomnolenceNervous system disorders3/341/32
VomitingGastrointestinal disorders0/341/32
AstheniaGeneral disorders0/341/32
Pruritus generalisedSkin and subcutaneous tissue disorders0/341/32
HyperhidrosisSkin and subcutaneous tissue disorders1/341/32
DysuriaRenal and urinary disorders0/341/32
DyspepsiaGastrointestinal disorders1/340/32

Baseline characteristics

Demographic data was analysed FAS set.

Age, Customized
Age, Customized(participants)Oxycodone HydrochlorideMorphine SulphateTotal
<39 years022
40-49 years123
50-59 years5611
60-69 years272249
Sex: Female, Male
Sex: Female, Male(Participants)Oxycodone HydrochlorideMorphine SulphateTotal
Female121022
Male212243
Region of Enrollment
Region of Enrollment(participants)Oxycodone HydrochlorideMorphine SulphateTotal
Korea, Republic of333265
08

Study locations

1 site
  • Seoul St. Mary's Hospital, The Catholic University of Korea
    Seoul, Korea, Republic of
09

References and documents

Publications

  • Lee KH, Kang JH, Oh HS, Choi MK, Shim BY, Eum YJ, Park HJ, Kang JH. Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study. Pain Res Manag. 2017;2017:9741729. doi: 10.1155/2017/9741729. Epub 2017 Oct 31. PubMed 29670416 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2016
First posted
Jan 21, 2016
Start
Nov 2015
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Nov 19, 2018
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02660229
Responsible party
Sponsor
First posted
Jan 21, 2016
Start date
Nov 2015
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Nov 19, 2018
Last update
Nov 19, 2018

Study contacts

Jinhyong Kang, Dr. Ph.D
principal investigator · Seoul St. Mary's Hospital, The Catholic University of Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion